Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial (2020)

Peer-Reviewed Study · Gallia GL, Holdhoff M, Brem H, Joshi AD, Hann CL, Bai RY, Staedtke V, Blakeley JO, Sengupta S, Jarrell TC, Wollett J, Szajna K, Helie N, Mattox AK, Ye X, Rudek MA, Riggins GJ · November 12, 2020

Gallia GL et al., 2020-11-12: Single-center phase 1 dose-escalation study of mebendazole plus temozolomide in 24 adults with newly diagnosed high-grade glioma. It reports acceptable toxicity up to 200 mg/kg/day and a median overall survival of 21 months.

Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years.

n/a

Gallia GL et al., 2020-11-12: Single-center phase 1 dose-escalation study of mebendazole plus temozolomide in 24 adults with newly diagnosed high-grade glioma. It reports acceptable toxicity up to 200 mg/kg/day and a median overall survival of 21 months. Study type: phase 1, single-arm dose escalation. N=24 (18 glioblastoma, 6 anaplastic glioma). Country: United States (Johns Hopkins). Dose: oral mebendazole 25, 50, 100 and 200 mg/kg/day with adjuvant temozolomide after chemoradiation; 15 patients at 200 mg/kg/day. Funder: Accelerate Brain Cancer Cure, NIH R01CA190223, Cures within Reach, and family gifts. Conflicts: G.J.R. founder of and equity in Benizole Therapeutics; H.B. research funding from Acuity Bio and consultancy/equity in several device companies. Maker: mebendazole supplied/manufactured with Accelerate Brain Cancer Cure support; specific manufacturer not stated in the abstract. Comparator: none (single arm); survival compared informally with historical data. Results: grade 3 ALT/AST in 4 patients at 200 mg/kg, reversible; median PFS 13.1 months in 17 patients on >1 month of mebendazole. Published online 2020-11-12; journal issue 2021;3(1):vdaa154. Also filed as MBB-70, MBD-11 (claims C2, C3, C7).